Detailed Quote
5i Report
Review of Knight Therapeutics
SEP 21, 2023 - The share price of GUD has declined over the years, while its fundamentals have been mixed. The company maintains a very strong balance sheet and has grown its top line nicely, but its profits have declined over the years leading to a questionable outlook. GUD has been a disappointment for many, us included. Due to some of its fundamentals maintaining their strength (balance sheet, revenue growth), we have kept it in our coverage list, however, we feel it has been held long enough and with declining margins, we are dropping coverage on Knight Therapeutics (GUD).
Download ReportCompany Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Would appreciate your comments on the recent quarterly report. Do you see any basis for the stock price to start increasing?
Q: Its been flat for 10 years now. Before Paladin Labs took off how long was the stock doing nothing before it was taken out? Are there signs that should monitored that will show things are about to inflect? They keep buying back lots of shares and presumably executing on their strategy.
Q: Hello ,
Are you able to provide a view as to why Cipher Pharma is doing so well stock wise and yet Knight is still in the doldrums? Also, is too late to step into Cipher Pharmaceuticals. I would appreciate your comments;
Are you able to provide a view as to why Cipher Pharma is doing so well stock wise and yet Knight is still in the doldrums? Also, is too late to step into Cipher Pharmaceuticals. I would appreciate your comments;
Insiders
Share Information
News and Media